【持续性肾脏替代治疗CRRT英文课件】Renal-Disease-Overview

(Symbol:XCPL)Rodman&Renshaw9thAnnualHealthcareConferenceNovember7,2007(Symbol:XCPL)1Forward-LookingStatements

Exceptforstatementsofhistoricalfact,themattersdiscussedinthispresentationareforwardlookingandpursuanttothesafeharborprovisionsoftheprivateSecuritiesLitigationReformActof1995.Theseforward-lookingstatementsreflectnumerousassumptionsandinvolveavarietyofriskanduncertainties,manyofwhicharebeyondthecompany’scontrolthatmaycauseactualresultstodiffermateriallyfromstatedexpectations.Theseriskfactorsinclude,amongothers,limitedoperatinghistory,difficultyindeveloping,exploiting,andprotectingproprietarytechnologies,theriskthatourtechnologymaynotbeeffective,uncertaintyastotheoutcomeoflegalproceedings,intensecompetition,andsubstantialregulationinthemedicaldeviceandhealthcareindustries,asdiscussedintheCompany’speriodicreportsfiledwiththeSecuritiesandExchangeCommission,availableonitswebsiteat.2Forward-LookingStatements Exc2CompanyOverviewMedicaldevicecompanyDevelopingandcommercializingextra-corporealmedicaldevicesthatwillreplacethefunctionoffailingorfailedorgansInnovativeplatformtechnologybelievedtobesuperiortothosecurrentlyinuseFocusingonthreerenalreplacementtherapyapplicationsarisingfromplatformtechnology

3CompanyOverviewMedicaldevice3【持续性肾脏替代治疗CRRT英文课件】Renal-Disease-Overview4【持续性肾脏替代治疗CRRT英文课件】Renal-Disease-Overview5

PortableHemodialysisDevice

for

HospitalCRRT/AcuteHemodialysis6

PortableHemodialysisDevice6AcuteRenalFailure-HospitalPrevalence>200,000/yearintheU.S.with50%mortality;majorityhospitalizedinICUsGrowingat10%peryearduetoagingpopulationandincreasingseverityofhospitalizedpatientsContinuousRenalReplacementTherapy(CRRT)isemergingtherapyofchoice24hour/7daytherapymimicsnormalkidneySlowandgentletherapy(Nosuddenvolumeshifts)AdoptionofCRRTlimitedbyLaborintensivetherapyExpensivereplacementfluid7AcuteRenalFailure-HospitalPr7Xcorporeal’s

HospitalRenalReplacementDeviceSmaller,trulyportabledevice(30-40lbs)Multifunctional–CRRT&IntermittentHDSorbent-baseddialysateregenerationDecreaseWorkloadforICUstaffNoplumbingrequirementsorbaggeddialysateSimpletouseoperatorinterfaceSnap-indisposableunitSimpleset-up,teardownCosteffectiveDecreaseinmedicalstafftime(nurse,pharmacist)Noneedforbaggeddialysate($180/treatment)8Xcorporeal’s

HospitalRenalR8

PortableHemodialysisDevice

for

HomeRenalReplacementTherapy9

PortableHemodialysisDevice

9ChronicRenalFailure75MAmericansatriskofdevelopingCRF9thleadingcauseofdeathintheUSNo“cure”andtherapyfocusesonslowingprogressiontoend-stagerenaldiseaseEnd-StageRenalDisease>350,000patientsreceivingdialysisHealthcareExpenditures~$32b/yrin20040.2%populationbut7%ofMedicarebudgetMature,cost-constrainedindustry10ChronicRenalFailure75MAmeri10HemodialysisforESRD90%ESRDpts.onHDMajorityofpatientsundergotherapy3x/wkatanoutpatientclinicfor3-4hours/sessionHighmorbidity:12-14dinthehospitalperyearMortalityintheUSremainshighestintheworld,~24%inYear1Totalcost=$100k/yr11HemodialysisforESRD90%ESRD11WhyanOpportunityforXcorporeal?RecognitionthatmorehemodialysistreatmentsproducebetterpatientoutcomesReducesmeds,e.g.erythropoietins(WWsales>$5B)ReduceshospitalizationsImprovesqualityoflifeInsurancecompanypotentialnetsavingsof25%Hemodialysisclinicsareexpensivetobuild,~$1.5Mfora20station,120patientunitMajorefficienciesalreadyachievedwithintheindustry–consolidation,verticalintegrationCost-constraints,pricecompressionCapitation:singlereimbursementrateBundlingofallservicesincludingmeds.onthehorizon12WhyanOpportunityforXcorpor12HomeHemodialysisisasignificantGrowthOpportunityinESRDPatientBenefitsIncreasedtimeonhemodialysiswithimprovedoutcomesPotentialfordailydialysisImprovedqualityoflife:diet,sleep,timeProviderBenefitsDecreasedneedfornurses/techsIncreaseinrevenueswithoutneedforadditionalinfrastructureDecreasedneedforexpensivemedications

13HomeHemodialysisisasignifi13Comparable–NxStageMedical,Inc.Emerginggrowthhemodialysiscompany“SystemOne”deviceHomehemodialysis:1,615patients;<0.5%marketHospitalCRRTforacuterenalfailureFinancialMetrics$517Mmarketcapitalization–10/25/07(Pro-forma)16.7xtrailingtwelvemonthsrevenues13.0xannualizedQ2,2007revenuesQuarterendedJune30,2007financialhighlights$53Mincash$17Moperatingexpenses$13.5Moperatingloss14Comparable–NxStageMedical,14WhywillXcorporeal’sHomeHemodialysisDeviceSucceed?MarketforcesdrivinghomehemodialysisPricecompressionMarketingeffortsofNxStageSmaller,portabledevice(30-40lbs)ImprovedflowratesrelativetoNxStageOpportunityforpatientswithhighBodyMassIndexCosteffectiveNowaterpurificationsystem(~$100K/center)Noneedforbaggeddialysate(~$360/month/patient)SimpletouseSimpleuserinterfaceSimplesetup,teardown15WhywillXcorporeal’sHomeHem15Comparisonof

HomeHemodialysisDevices16

Fresenius2008KRenalSolutionsNxStageXcorpBloodFlowRates20-600150-40050-60010-600DialysateFlowRates100-800200-40050-20010-500Dialysate/4-hr(Liters)120620-302-4DialysateRegenerationNoYesNoYesDryWeight(lbs)1601958030-40Size(cuft)161651.5PortableNoNoPartialYesDrainageRequiredYesNoYesNoInstallationCostHighLowLowLow

Comparisonof

HomeHemodialysi16

WearableArtificialKidney17

WearableArtificialKidney1717WearableArtificialKidney“Disruptive”technologyWearable,light-weightdeviceBatteryoperatedFullyautomated,simpletouseDialysateregenerationwithsorbents24hrs/7daystherapywithpotentialtorevolutionizecareofESRDpatients18WearableArtificialKidney“Dis18WearableArtificialKidneyInitialclinicalstudyconductedwithaprototypedeviceatTheRoyalFreeHospital,London8ESRDsubjectsdialyzedformeanof6.4hrsClearancesofcreatinine,urea,andbeta-2-microglobulinachievedNoadverseeventsreportedSubjectsambulatedbothuntetheredandw/oimpactondeviceperformanceCompellingdatapresentedatASNNovember5,2007Publicationsubmittedtopeerreviewjournal19WearableArtificialKidneyInit19RegulatoryStrategyDeviceU.S.E.U.ClinicalTrialsCRRT/AcuteHD510(k)CENoneHomeHemodialysis510(k)CE30-40patientsWearableArtificialKidneyPMACE100-200patients20RegulatoryStrategyCRRT/Acute20Xcorporeal’sProducts

AnticipatedApprovalDatesDeviceE.U.U.S.PortableHemodialysisDevice

-CRRT/AcuteHemodialysisQ4’08Q1’09PortableHemodialysisDevice-HomeHemodialysis-ESRDQ4’08Q2’09WearableArtificialKidney

-HomeHemodialysis-ESRD2010201221Xcorporeal’sProducts

Anticipa21ReimbursementCodes(CMS/Medicare)areEstablishedProcedureCodeAmountCommentsUltrafiltrationAquapheresis36514$720/txCodeforplasmapheresisAcuteHD90935$406/txCRRT90935$406/txHomeHD9092590921$1800/moIncludesallHDsuppliesOutpatientHD9092590921$96-123/txVariesdependingonregion22ReimbursementCodes(CMS/Medic22RenalReplacementTherapyMarketOpportunity$inmillionsUSEuropeAsiaTotalHospitalRenalReplacementDevice:Disposables$968$660$484$2,112Device$465$465$232$1,162TotalHospitalRRDevice$1,433$1,125$716$3,274ESRD-HomeRenalReplacementDevice

andWearableArtificialKidney:TotalHomeRRDandWAK$7,074$7,146$3,537$17,757TotalAllDevices$8,507$8,271$4,253$21,03123RenalReplacementTherapyMark23ManagementTeamTerrenPeizer ExecutiveChairmanWinsonTang,MD,

FACP

ChiefOperatingOfficerVictorGura,MD

ChiefMedicalOfficerRobertWeinstein,CPA,MBA

ChiefFinancialOfficerCEO,Chairman&FounderHythiamAmgen,Vertex,Tularik,Isis,PacificCapitalGrpCedars-SinaiMedCntr,AssocClinProf,UCLACitiPrivateEquity,AbleLabs,GECapital24ManagementTeamTerrenPeizerC24ManagementTeamNinaPeled,PhD,MBA SVP-Quality&RegulatoryJamesBraig,MSME

SVP-ProductDevBarryFulkerson

VP-HardwareSystemsRussJoseph,MS

VP-DisposableEngineerHansen,Cygnus,Amira,Lumenis,i-STAT,BMOptiscan,SquareOneTech,OhioMedicalNxStage,COBE(Prisma,CS3),GambroGishBiomedical,Sorin,BaxterHealthcare25ManagementTeamNinaPeled,PhD25ProductDevelopmentTeamInternalteamofengineerswithexpertiseindialysisequipmentanddisposableswhopreviouslyworkedatCobe,Gambro,Aksys,NxStageandBaxterContractProductDevelopmentGroupinSouthernCaliforniatoleveragetheexpertiseofanadditional10-15engineersManufacturingtobeoutsourced26ProductDevelopmentTeamIntern26SelectedBoardMembersand

ScientificAdvisorsHansPolaschegg,PhDDanGoldberger,MSMEKellyMcCrann,MBAFresenius-(A1008D,2008D,2008H)Chairman,ExtracorpCir&InfusionTechComGlucon,OSISystems,Optiscan,NellcorDaVita,PacificCare,ProfDentalAssoc,KPMG,McKinsey27SelectedBoardMembersand

Sci27SelectedFinancialInformation

($inmillions)BalanceSheet–June30,2007: -CashandMarketableSecurities $23.0 -Totalassets

$23.3 -Totalliabilities $1.9 -Totalstockholders’equity